A 65-year-old woman with severe paravalvular mitral regurgitation and chronic hemolytic anemia was referred for surgical consultation. Her medical history included rheumatic heart disease with mitral valve replacement in 1977, aortic valve replacement in 1988, and repeat mechanical mitral valve replacement in 2002. Predominant symptoms were New York Heart Association function class III dyspnea and fatigue. The patient was considered at high risk for surgical complication because of the 3 previous valve surgeries and significant pulmonary hypertension (systolic pulmonary pressure, 70 mm Hg).
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The Figure fluoroscopy were used to confirm unrestricted mechanical leaflet motion. This 3D image (panel G; Movie III) is cropped to create a unique lateral 2-chamber perspective and demonstrates the mushroom shape of the deployed occluder against the circular contour of the prosthetic valve annulus. Significant reduction in paravalvular systolic flow is demonstrated by 2D color Doppler (panel H; compare with panel A).
Procedural success was confirmed by Doppler hemodynamic parameters before and 5 days after paravalvular repair. Postprocedure study demonstrated a reduction of mitral inflow mean pressure gradient (from 5.7 to 3.8 mm Hg, both studies at 70 bpm). In addition, a dramatic decrease in the degree of hemolysis was observed. Before closure, hemoglobin was 8.7 gm/dL, total bilirubin was 3.8 mg/dL, ferritin was 598 ng/mL and LDH was 2935 U/L. Four days after closure, hemoglobin remained stable, total bilirubin decreased to 0.8 mg/dL, and LDH decreased to 1066 U/L. Acutely, the patient's symptoms also improved from New York Heart Association class III to class II dyspnea.
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